Oct. 30, 2025 -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend of Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity funding round. DefEYE was esta

October 28, 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, is pleased to announce a research collaboration with a leading US clinic to further broaden the feasibility and manufacturing of research-scale Swarm-T cell preparations by using samples from patients treated in the clinic’s cancer vaccine studies. This research collaboration further expands Swarm’s

October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline, have ceased trading on the Nasdaq Stock Market LLC and Tourmaline is now an indirect wholly owned subsidiary of Novartis. “The acquisition of Tourmaline Bio aligns with our strategy to deepen expertise in areas where Novartis can lead and ad

Oct. 24, 2025 -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the closing of the transactions under the asset and share purchase agreement by and among the Company, Miza III Ventures Inc. and SciSparc Nutraceuticals Inc. (the “Agreement”). Pursuant to the Agreement, SciSparc received a controlling interest in N

Oct. 21, 2025 -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the Journal of Clinical Oncology (JCO). The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind,

Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG. New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%. Closing releases final $2.5 million of $11 million financing led by existing investors Rosalind Advisors and AIGH Capital Management, which is expected to fund Biofrontera Inc. to profitability. Oct. 23, 2025 -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofron

October 21, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97.00 per Common Share in cash (the “Offer Consideration”), less any applicable withholding taxes and without interest. The Offer is being made pursuant to the previously announ

Oct. 20, 2025 -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of a U.S. patent application by the United States Patent and Trademark Office. The patent relates to an innovative combination therapy of MEAI

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer Oct. 21, 2025 -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a collaboration with Memorial Sloan Kettering Cancer Center’s (MS

Oct. 21, 2025 -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, dosed first patients in its two randomized, double-blind, multicenter global Phase 3 trials, the RUBY study (NCT07089875) and the TOPAZ study (NCT07089888), evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor with potential for bes